Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences Ltd. announced a change in the director’s interest, with Gavin Fox-Smith acquiring a significant number of securities, including ordinary shares and options. This acquisition, approved at the Annual General Meeting, reflects strategic moves within the company to align leadership interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. operates in the biotechnology industry, focusing on the development of medical diagnostics. The company is primarily engaged in creating innovative solutions for early detection of diseases, with a market focus on improving patient outcomes through advanced diagnostic technologies.
Average Trading Volume: 343,535
Technical Sentiment Signal: Buy
Current Market Cap: A$28.99M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.